Evaluate Vantage Homepage
World ADC 2023 – targeting the folate receptor rises from the ashes
Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.
Europe rues SVB loss as a cornerstone life science supporter
With deeps links to the US likely severed, and HSBC’s risk appetite unknown, what does a future without Silicon Valley Bank look like?
Morphic looks to justify “oral Entyvio” excitement
Big hopes have built behind Morphic’s MORF-057 in ulcerative colitis, and a key trial reads out imminently.
Company Events
Morphic looks to justify “oral Entyvio” excitement
Big hopes have built behind Morphic’s MORF-057 in ulcerative colitis, and a key trial reads out imminently.
Altimmune aims to build Momentum in obesity
A readout in the next few weeks could put pemvidutide on course for blockbuster sales – or not.
Go or no go? Vaccines and neurology up for discussion
FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.
Interviews
Novo sows the seeds for a new heart failure approach
The company reckons it can succeed where other cell therapies have failed, but proof is a long way off.
Spybiotech seeks new vaccines
With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic.
Biohaven looks to seize a new opportunity
The post-Pfizer pipeline looks disparate, but the group insists there is a method to its fast-follower approach.